
Publikationen von Uwe Möginger
Alle Typen
Zeitschriftenartikel (6)
2018
Zeitschriftenartikel
8, 70 (2018)
Alterations of the human skin N- and O-glycome in basal- and squamous cell carcinoma. Frontiers in Oncology 2016
Zeitschriftenartikel
76 (2), S. 403 - 417 (2016)
An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo. Cancer Research
Zeitschriftenartikel
6, 20488 (2016)
Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites. Scientific Reports 2014
Zeitschriftenartikel
101, S. 205 - 216 (2014)
Proteomics on porcine haptoglobin and IgG/IgA show protein species distribution and glycosylation pattern to remain similar in PCV2-SD infection. Journal of Proteomics 2013
Zeitschriftenartikel
12 (10), S. 2935 - 2951 (2013)
Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Molecular and Cellular Proteomics
Zeitschriftenartikel
11 (33), S. 5399 - 5403 (2013)
β(3R3)-peptides: design and synthesis of novel peptidomimetics and their self-assembling properties at the air-water interface. Organic & Biomolecular Chemistry Meeting Abstract (3)
2016
Meeting Abstract
69, 440, S. S144. Pergamon, Oxford, UK (2016)
Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by Fc-engineering of IgA antibody against the epidermal growth factor receptor. In European Journal of Cancer,
Meeting Abstract
39 (Suppl. 3), P276, S. 83 - 84. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Leipzig, 14. Oktober 2016 - 18. Oktober 2016. Karger, Basel, Schweiz (2016)
Glyco- and Fc engineering of IgA antibodies for cancer immunotherapy improved pharmacokinetics & myeloid effector cell engagement. In Oncology Research and Treatment, 2015
Meeting Abstract
33 supplement Aufl., abstract 3037. 2015 ASCO Annual Meeting. Grune & Stratton, New York, NY (2015)
Pharmacokinetics and myeloid effector cell engagement of an engineered IgA antibody against the epidermal growth factor receptor. In Journal of Clinical Oncology,